Enterprise AI Diagnostics LumineticsCore is FDA-authorized to diagnose diabetic retinopathy with autonomous AI, enabling health systems and diagnostic networks to deploy scalable screening without additional clinician time. Partnerships with OSF HealthCare and LabCorp demonstrate real-world deployment and revenue opportunities within large care networks.

Global Partnerships International collaboration with Magrabi Health to launch LumineticsCore in Riyadh signals a strong pathway to replicate diabetic retinopathy screening programs across regional hospital groups and eye care networks. Channel partnerships and regional health networks offer a scalable route for geographic expansion.

IT Integration The platform relies on cloud and enterprise-ready infrastructure (Google Cloud, AWS, RabbitMQ) and integrates with common IT tools, simplifying EHR and data-system compatibility. This reduces deployment risk for health systems and labs, improving time-to-value and adoption likelihood.

Financial Validation Strong financing and strategic backing validate the market, reducing sales cycle friction for large health networks and diagnostic labs. Financial backing signals long-term opportunity for multi-site deployments and enterprise agreements.

Product Expansion As Digital Diagnostics expands into additional diagnostic capabilities, existing customers can be upsold to a broader AI diagnostics platform, extending value across ophthalmology, neurology and related imaging pathways.